Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

GlobalData expects that the US will contribute the most to the growth of the heart failure market due to the higher ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Just type in #weightloss on any social media platform today and you'll be met with everything from intermittent fasting diets ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...